Bloomage Biotech(SH:688363) Shenwan Hongyuan Securities·2025-10-30 08:12Investment Rating - The investment rating for the company is "Outperform" (maintained) [2] Core Insights - The company reported a revenue of 3.163 billion yuan for the first three quarters of 2025, a year-on-year decrease of 18.36%, while the net profit attributable to the parent company was 252 million yuan, down 30.29% [7] - In Q3 2025, the company achieved a revenue of 903 million yuan, a year-on-year decline of 15.16%, but the net profit increased by 55.63% to 31.53 million yuan [7] - The company is focusing on high-quality development and has reduced sales expenses significantly, leading to the lowest sales expense ratio in five years at 34.26% [7] - The company is enhancing its research and development capabilities, particularly in high-end raw materials and medical terminal businesses, while also exploring brand building in skincare [7] Financial Data and Profit Forecast - Total revenue for 2025 is estimated at 4.789 billion yuan, with a year-on-year decline of 10.8% [6] - The net profit for 2025 is projected to be 425 million yuan, representing a significant increase of 143.8% compared to the previous year [6] - The company’s gross margin is expected to be 71.6% in 2025, with a return on equity (ROE) of 5.9% [6] - The earnings per share (EPS) for 2025 is forecasted to be 0.88 yuan [6] Business Segments - The raw materials business generated revenue of 923 million yuan in the first three quarters of 2025, with a gross margin of 84.81% [7] - The medical terminal business achieved revenue of 1.031 billion yuan, with a 14.51% year-on-year growth in Q3 2025 [7] - The skincare innovation segment is undergoing transformation, focusing on long-term technological advantages and product conversion [7]